AFT Pharmaceuticals
AFT.NZAFT.NZ · Stock Price
Historical price data
Overview
AFT Pharmaceuticals is a publicly listed, integrated pharmaceutical company with a mission to develop and commercialize innovative products that address unmet health needs. Founded in 1997, it has achieved consistent revenue growth by leveraging a dual strategy of in-licensing/distribution and proprietary R&D, most notably with its world-first Maxigesic® combination analgesic platform. The company has successfully expanded from its New Zealand base to establish a significant presence in Australia, Asia, and Europe, demonstrating robust commercial execution and a focus on niche therapeutic areas like pain management, ophthalmology, and gastroenterology.
Technology Platform
Patented Maxigesic® platform combining paracetamol and ibuprofen for synergistic pain relief, supported by formulation expertise for oral, IV, and combination products, and a liposomal delivery technology for nutraceuticals.
Pipeline
8| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Combogesic® IV (fixed-dose combination containing acetaminop... | Acute Pain | Phase 3 | |
| Maxigesic IV + IV Acetaminophen + IV Ibuprofen + Placebo IV | Post Operative Pain | Phase 3 | |
| Maxigesic 325 + Acetaminophen + Ibuprofen + Placebo | Dental Pain | Phase 3 | |
| Maxigesic® IV | Postoperative Pain | Phase 3 | |
| Acetaminophen + Maxigesic 325 + Ibuprofen + Placebo | Osteoarthritis | Phase 3 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Competes in pain management against generic analgesics, branded single-agent products, and other non-opioid protocols. In its portfolio business, faces localized competition from generic and branded products in each therapeutic category. Differentiates via patented combinations, clinical data, and niche market focus.
